These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22696079)

  • 1. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.
    Gabler NB; French B; Strom BL; Palevsky HI; Taichman DB; Kawut SM; Halpern SD
    Circulation; 2012 Jul; 126(3):349-56. PubMed ID: 22696079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole?
    Farber HW
    Circulation; 2012 Jul; 126(3):258-60. PubMed ID: 22696078
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat for the treatment of pulmonary arterial hypertension.
    Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
    N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
    Gabler NB; French B; Strom BL; Liu Z; Palevsky HI; Taichman DB; Kawut SM; Halpern SD
    Chest; 2012 Jan; 141(1):20-26. PubMed ID: 21940766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
    Duo-Ji MM; Long ZW
    Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are hemodynamics surrogate end points in pulmonary arterial hypertension?
    Ventetuolo CE; Gabler NB; Fritz JS; Smith KA; Palevsky HI; Klinger JR; Halpern SD; Kawut SM
    Circulation; 2014 Aug; 130(9):768-75. PubMed ID: 24951771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current treatment of pulmonary arterial hypertension: time to redefine success.
    Rich S
    Chest; 2006 Oct; 130(4):1198-202. PubMed ID: 17035456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
    Ryerson CJ; Nayar S; Swiston JR; Sin DD
    Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.
    Souza R; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Le Brun FO; Mehta S; Perchenet L; Pulido T; Sastry BKS; Sitbon O; Torbicki A; Rubin LJ; Simonneau G
    PLoS One; 2018; 13(3):e0193226. PubMed ID: 29590122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.
    Coeytaux RR; Schmit KM; Kraft BD; Kosinski AS; Mingo AM; Vann LM; Gilstrap DL; Hargett CW; Heidenfelder B; Dolor RJ; McCrory DC
    Chest; 2014 May; 145(5):1055-1063. PubMed ID: 24371842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.
    Kawut SM; Bagiella E; Lederer DJ; Shimbo D; Horn EM; Roberts KE; Hill NS; Barr RG; Rosenzweig EB; Post W; Tracy RP; Palevsky HI; Hassoun PM; Girgis RE;
    Circulation; 2011 Jun; 123(25):2985-93. PubMed ID: 21593252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis.
    Badiani B; Messori A
    Heart Lung Circ; 2016 Jan; 25(1):46-52. PubMed ID: 26233257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
    Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
    Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.
    Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Blank K; Grinnan D; Holmes JH; Mathai SC; Minhas J; Ventetuolo CE; Zamanian RT; Kawut SM
    Am J Respir Crit Care Med; 2023 Apr; 207(8):1070-1079. PubMed ID: 36629737
    [No Abstract]   [Full Text] [Related]  

  • 20. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.
    Galiè N; Manes A; Negro L; Palazzini M; Bacchi-Reggiani ML; Branzi A
    Eur Heart J; 2009 Feb; 30(4):394-403. PubMed ID: 19155250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.